Key result
STEMI and NSTEMI show similar nonculprit major cardiovascular events rates and vulnerable plaque prevalence over ~4 years.
Why the study?
Clinical guidelines recommend different revascularization strategies for nonculprit lesions in STEMI versus NSTEMI, but whether the prevalence of untreated high-risk vulnerable plaques differs between them and affects outcomes was unknown.
Does the prevalence of untreated high-risk vulnerable plaques and their outcomes differ between patients with STEMI and NSTEMI?
Cohort
Yes
Does the prevalence of untreated high-risk vulnerable plaques and their outcomes differ between patients with STEMI and NSTEMI?
High-risk vulnerable plaques and nonculprit lesion-related MACE occur at similar rates in STEMI and NSTEMI, suggesting nonculprit revascularization strategies should be similar for both.
Answers are grounded in this paper and cite their sources.
Supports similar nonculprit risk assessment in STEMI and NSTEMI; leaves open randomized confirmation before practice change.
BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment-elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI). Whether the prevalence of untreated high-risk vulnerable plaques differs in STEMI and NSTEMI and affects their outcomes is unknown. METHODS: In PROSPECT II (Providing Regional Observations to Study Predictors of Events in the Coronary Tree II), a multicenter, prospective natural history study, patients with recent myocardial infarction underwent 3-vessel coronary angiography with coregistered near-infrared spectroscopy and intravascular ultrasound after successful percutaneous coronary intervention of obstructive lesions from 2014 through 2017. Two-feature high-risk plaques were defined as those with both plaque burden ≥70% and maximum lipid core burden index over any 4-mm segment ≥324.7. The primary end point was major adverse cardiovascular events arising from untreated nonculprit lesions during a median 3.7-year follow-up. CONCLUSIONS: In the PROSPECT II study, the per-patient prevalence of high-risk vulnerable plaques was comparable in STEMI versus NSTEMI, as was the overall long-term incidence of nonculprit lesion-related and all major adverse cardiovascular events. These results support a similar revascularization strategy for nonculprit lesions in patients with STEMI or NSTEMI after culprit lesion management. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02171065.
No takes yet. Share an insight, caveat, or question.
Thrane et al. (2025) conducted a cohort in Myocardial infarction (STEMI vs NSTEMI). ST-segment-elevation myocardial infarction (STEMI) with untreated nonculprit vulnerable plaques vs. Non-ST-segment-elevation myocardial infarction (NSTEMI) was evaluated on Major adverse cardiovascular events arising from untreated nonculprit lesions (p=0.80). STEMI and NSTEMI patients had comparable prevalence of high-risk vulnerable plaques and 3.7-year incidence of nonculprit lesion-related major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: